Olaparib (AZD2281, Ku-0059436)

目录号:S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。

规格 价格 库存 购买数量  
RMB 745.41 现货
RMB 571.54 现货
RMB 1219.52 现货
RMB 3019.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献83篇:

客户使用该产品的18个实验数据:

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。
特性 Olaparib是第一批PARP抑制剂之一。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
体外研究

Olaparib是PARP抑制剂,也作用于BRCA1或BRCA2突变。Olaparib对端锚(聚合)酶-1作用效果不大,IC50值大于。Olaparib浓度为30-100 nM作用于SW620细胞,使PARP-1失活。与BRCA1和BRCA2充足细胞系(Hs578T,MDA-MB-231,T47D)相比,BRCA1缺陷细胞系(MDA-MB-463和HCC1937)对Olaparib过分敏感[1] Olaparib抑制PARP,阻断碱基切除修复,导致KB2P细胞对Olaparib强烈敏感。结果导致在DNA复制时由单链断裂转变为双链断裂,由此激活BRCA2依赖的重组途径。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrJOEBl NEnwd5RKSzVyPUWuO|A2KCEQvF2g NFHRSYcyQDV3OU[xNy=>
KP6.3 NUf6TXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PrWVQh\A>? NEXlOnNKSzVyPUGwMlQzQCEQvF2g M1foVFE5PTV7NkGz
KP7.7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL2N|RIPCCm M{HpSmlEPTB;NUegcm0h NUSycVhsOTh3NUm2NVM>
KB2P3.4 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH21O5I1KGR? MY\JR|UxRTF{NDDNJC=> MWGxPFU2QTZzMx?=
KB2P1.21 NGfxWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fXN|Qh\A>? NGfOdG9KSzVyPUi5NFchdk1i MVexPFU2QTZzMx?=
U373-MG MnH3R5l1d3SxeHnjJGF{e2G7 NFzte|cyKM7:TTC= NUjETpNGOjRiaB?= MoGwTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? MXGxPFk2PDdzMh?=
T98G MmLuR5l1d3SxeHnjJGF{e2G7 NVPmfoVsOSEQvF2g NGq4TVQzPCCq MXfJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 Mn7iNVg6PTR5MUK=
U87-MG MXTDfZRwfG:6aXOgRZN{[Xl? NHrJOVkyKM7:TTC= MkfTNlQhcA>? MYTJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 MUSxPFk2PDdzMh?=
UVW MWfDfZRwfG:6aXOgRZN{[Xl? Mnn2OVAxKG6P MYOyOEBp NGTyT|FKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 MkPtNVg6PTR5MUK=
HeLa NF3XRnZHfW6ldHnvckBCe3OjeR?= MW[1NFAhdk1? MXi0JIg> NIPYSpJE[XW|ZYOgZUBud2Snc4Sg[IVt[XliaX6gdoVrd2mwaX7nJI9nKHKjZHnheIlwdi2rbnT1Z4VlKESQQTDidoVic3N? MlixNVg6PTR5MUK=
HeLa NELye|BHfW6ldHnvckBCe3OjeR?= NF7RRnUyKM7:TTC= NFj5NmIzPCCq MXvFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? NXvWTHJ6OTh7NUS3NVI>
T98G MlfwSpVv[3Srb36gRZN{[Xl? NYjCTZZFOSEQvF2g MWWyOEBp NGC3OZlGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= MnvONVg6PTR5MUK=
L3 MXPDfZRwfG:6aXOgRZN{[Xl? NUTvdG55PSEQvF2g M37aPVk3KGh? M{O1NWROW09? MVvTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= NF;Jbo8zODF{NES1PS=>
Granta-519 NIT0R4ZEgXSxdH;4bYMhSXO|YYm= MlLjOUDPxE1i NV3EOGhZQTZiaB?= M4rk[GROW09? MVzTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MV:yNFEzPDR3OR?=
BT NG\VWlZEgXSxdH;4bYMhSXO|YYm= M{nD[VUh|ryPIB?= M4rXfVk3KGh? MYjEUXNQ MXPTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NI\rN3MzODF{NES1PS=>
UPN2 MmfmR5l1d3SxeHnjJGF{e2G7 MXS1JO69VSB? NWfOZWtWQTZiaB?= MVvEUXNQ Mm\jV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NE[yN4EzODF{NES1PS=>
HBL-2 MXPDfZRwfG:6aXOgRZN{[Xl? NVnYdXI3PSEQvF2g M{DmZVk3KGh? MkC2SG1UVw>? NGjlXZJUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NXvqSGJyOjBzMkS0OVk>
JVM-2 MluzR5l1d3SxeHnjJGF{e2G7 NFPubWY2KM7:TTC= MlL3PVYhcA>? NE\NSIpFVVOR NEX5VnVUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NFXXT|EzODF{NES1PS=>
Z138 NXHiW5RvS3m2b4TvfIlkKEG|c3H5 MoSwOUDPxE1i Mn;QPVYhcA>? MlHVSG1UVw>? NIHmR4JUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NGW4[lEzODF{NES1PS=>
RWPE MYrJcpZie2m4ZTDBd5NigQ>? NIHPXXMzPSEQvF2= NWPVR3pwPDhiaB?= MnK5SG1UVw>? Mkj2V4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> M3L0dlIyPTd3OE[1
VCaP NG\sR2lKdn[jc3n2[UBCe3OjeR?= M3zvc|I2KM7:TR?= MoX0OFghcA>? MnzISG1UVw>? M1HFZnNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> NYT2emJKOjF3N{W4OlU>
Mouse H2AX−/− ES Cells NXXMOHNxS3m2b4TvfIlkKEG|c3H5 M1Hr[FIvPSEQvF2= MUmyNEBp NFK1W|dUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> M4PwXVI{OzV3NEi5
Mouse ATM−/− ES Cells MmrpR5l1d3SxeHnjJGF{e2G7 NYS4epU6Oi53IN88US=> M{nFVVIxKGh? MmO1V4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NEnpfZgzOzN3NUS4PS=>
H1650 NUL6bJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHqb2puOjBizszN NWDiR3Y6OTR2IHi= M3ziemlEPTB;MUWuOFch|ryP MWKyN|I{QThyOR?=
H1650PTEN+ MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmyNEDPxE1? NFm1TXYyPDRiaB?= MlnPTWM2OD13MD64N{DPxE1? MWWyN|I{QThyOR?=
PC-9 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfBTIQzOCEQvF2= MYexOFQhcA>? M2H5S2lEPTB;NT64PEDPxE1? NUKwTHNQOjN{M{m4NFk>
PC-9PTEN− NGjZd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLJd2gzOCEQvF2= MUKxOFQhcA>? NHvqfplKSzVyPU[uOVIh|ryP NGfad5IzOzJ|OUiwPS=>
MDA-MB-231 M4XxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHwbGQ2KGSjeR?= MVvJR|UxRTZwOTFOwG0> NHLyXHUzOzd4MES5Oi=>
MDA-MB-468 NXrHWlZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XDNlUh\GG7 M2TrWmlEPTB;NT6wJO69VQ>? M2LmTFI{PzZyNEm2
BT20 NIj5SFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\QRZUxPSCmYYm= M4HZOGlEPTB;Nz63JO69VQ>? MkjSNlM4PjB2OU[=
HCC1143 M{D0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn3b|R[PSCmYYm= NF;r[HpKSzVyPUGxMlEh|ryP Mn7sNlM4PjB2OU[=
HCC1937 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL2flFDPSCmYYm= NVHEVZNWUUN3ME2xNk43KM7:TR?= NFHTfHgzOzd4MES5Oi=>
Hs578t MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHY[pA2KGSjeR?= M{PCdGlEPTB;NT62JO69VQ>? M4Hj[VI{PzZyNEm2
Hs578t(si) M4W2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fPWlUh\GG7 NXvORXpVUUN3ME23MlUh|ryP M1TwSlI{PzZyNEm2
BT474 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rNdVUh\GG7 NEfvWpFKSzVyPUG5Mlgh|ryP MYCyN|c3ODR7Nh?=
JIMT1 NUfySHZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGezVlM2KGSjeR?= NIniU2dKSzVyPUeuO{DPxE1? NWLjfFVOOjN5NkC0PVY>
SKBR3 M4Pyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW1JIRigQ>? NHfUe|VKSzVyPUGxMlEh|ryP NUnUPW9zOjN5NkC0PVY>
SUM159 M4P0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\FXWU2KGSjeR?= M1W3b2lEPTB;ND6yJO69VQ>? NGXhenkzOzd4MES5Oi=>
CAMA1 NXHjbotHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO1JIRigQ>? NFXtS|JKSzVyPUG1Mlgh|ryP M1LlbFI{PzZyNEm2
MCF7 M2DqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq1JIRigQ>? M37SW2lEPTB;NT64JO69VQ>? NVvhTIlPOjN5NkC0PVY>
T47D M{TLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C2UFUh\GG7 NGTJdpRKSzVyPUmuOkDPxE1? MY[yN|c3ODR7Nh?=
HCT116 NF;YNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorYNVAxKM7:TR?= NGP1d|A1QCCq M1PGe2ROW09? NE\zcpBKSzVyPUKuOUDPxE1i M2fBVlI1PTd5OUSx
SW1116 M3LwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPKOJhGOTByIN88US=> MWm0PEBp NUnFVXB7TE2VTx?= NHvRV2JKSzVyPUGwNEDPxE1? MmHrNlQ2Pzd7NEG=
HT29 NUfhcHJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPYNmMyODBizszN NHTZd401QCCq MVPEUXNQ NXrQTFdEUUN3ME2xOE44KM7:TR?= MWKyOFU4Pzl2MR?=
LoVo MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrBR3YyODBizszN NXnL[mY5PDhiaB?= NYLBS|FUTE2VTx?= NInW[FFKSzVyPUGzMlQh|ryP M1rrelI1PTd5OUSx
HCT-15 M{W4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX5cIg5OTByIN88US=> MVS0PEBp NX\ucWZOTE2VTx?= MXjJR|UxRTFyIN88US=> MXSyOFU4Pzl2MR?=
SW48 NWD1PVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKxNFAh|ryP M1HRelQ5KGh? MYDEUXNQ NWXsbZZKUUN3ME25MlUh|ryP NGDYNFUzPDV5N{m0NS=>
C-1 NYPIWYk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSxNFAh|ryP M{TOblQ5KGh? NWXZU3kxTE2VTx?= Ml\pTWM2OD15Lk[g{txO M4fudVI1PTd5OUSx
RKO M{Ppb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpZlExOCEQvF2= M2nNcVQ5KGh? NVPYVFVZTE2VTx?= NGPCcHBKSzVyPUWuPUDPxE1? NVLIWZV[OjR3N{e5OFE>
HCT116 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml35NVAxKM7:TR?= MUC0PEBp Mn\XSG1UVw>? NY\kc45yWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MX[yOFU4Pzl2MR?=
SW1116 NF3UZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT3dXEyODBizszN MYW0PEBp MnTuSG1UVw>? NETXfIdRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MV:yOFU4Pzl2MR?=
HT29 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13WTFExOCEQvF2= NI\nW4U1QCCq NVLoXGRwTE2VTx?= NWPJO4llWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NGDOcJEzPDV5N{m0NS=>
LoVo MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H1OlExOCEQvF2= NV:xOW43PDhiaB?= MUjEUXNQ NGfK[ZlRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli Mn;TNlQ2Pzd7NEG=
SW48 M2S3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\5NVAxKM7:TR?= NYTWXmMyPDhiaB?= MVHEUXNQ M{LXU3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NWPKOllsOjR3N{e5OFE>
C-1 M4rWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSxNFAh|ryP M1jlUlQ5KGh? M3LqRmROW09? NUfrbXlUWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MV6yOFU4Pzl2MR?=
RKO M1L1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjHeXgyODBizszN NYHmOnduPDhiaB?= MnWwSG1UVw>? MnjCVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NXTLXoU6OjR3N{e5OFE>
HCT116 MWDGeY5kfGmxbjDBd5NigQ>? M4KzV|ExKG6P MX[xNkBp M4ezSmROW09? NYf5cZJEUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 NVvTV2RxOjR3N{e5OFE>
HT29 MXvGeY5kfGmxbjDBd5NigQ>? MXKxNEBvVQ>? NHvBOlAyOiCq MX;EUXNQ MXfJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? M1Lv[lI1PTd5OUSx
TE-6 NGGze2lHfW6ldHnvckBCe3OjeR?= MXW1JO69VSB? MkfrNVIhcA>? MnThSG1UVw>? NELvZmxKdmS3Y3XzJGczN01iYYLy[ZN1 NF2y[G4zPDJzOUG2OC=>
TE-6 NWC4eIJ{TnWwY4Tpc44hSXO|YYm= Mo\wOUDPxE1i Mlm3NlQhcA>? NXzwXJFkTE2VTx?= M{nNXWlv[3KnYYPld{BqdiCmb4XicIUhe3S{YX7kJIJz\WGtczCoSHNDeyl? NUG2UmNIOjR{MUmxOlQ>
Hep3B MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XEflQxKM7:TTC= Mn3TO|IhcA>? M{XpOGROW09? NH7kTZVUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? MXeyOVA4Ojd3Mh?=
Huh7 NWLqeZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfIPXpsPDBizszNJC=> NVLYSGNuPzJiaB?= MXnEUXNQ M{HzdHN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS NIPEOWMzPTB5Mke1Ni=>
Hep3B MkfBSpVv[3Srb36gRZN{[Xl? Mn;FOFAh|ryPIB?= MUCyOEBp M4nXZmROW09? Mln0TY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT M2q1dlI2ODd{N{Wy
Huh7 MYHGeY5kfGmxbjDBd5NigQ>? M4D1XlQxKM7:TTC= Mlv6NlQhcA>? Mmn3SG1UVw>? MVvJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? Moe3NlUxPzJ5NUK=
Hep3B M2niXWZ2dmO2aX;uJGF{e2G7 MXq0NEDPxE1i M{jvOlI1KGh? Mn7kSG1UVw>? M1v0N2lv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= MnzZNlUxPzJ5NUK=
Huh7 M3\lSmZ2dmO2aX;uJGF{e2G7 NGnnN441OCEQvF2g NVLVZndGOjRiaB?= M2TCcWROW09? MmfRTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT MWCyOVA4Ojd3Mh?=
SGC-7901 NYjDVno2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[zNOKh|ryP MWC0PEBp MnruSG1UVw>? NH[0b|BDdG:lazDvfIFtcXCuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NYSwbmhOOjV5NkewO|Y>
COLO-800 NHT0Sm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLPTWM2OD1yLkS0NVY1KM7:TR?= M3\RdnNCVkeHUh?=
EoL-1- NEH1TFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;QTWM2OD1yLkW2OFQ3KM7:TR?= NHTSdJdUSU6JRWK=
NCI-H209 NH\j[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwOUG1OVYh|ryP M1XmVHNCVkeHUh?=
ES1 NXXzNVBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwMUG0NFgh|ryP NYixSGtnW0GQR1XS
NKM-1 NYPjV3lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwMkWzOFch|ryP M4nrc3NCVkeHUh?=
NTERA-S-cl-D1 NF7sc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwM{OzOFEh|ryP M33DXXNCVkeHUh?=
MHH-ES-1 NXLDSm9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfnfHdzUUN3ME2xMlYzODZ5IN88US=> M1vh[HNCVkeHUh?=
ES8 NGHVVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfvXoFmUUN3ME2xMlczPDF2IN88US=> M2\qbHNCVkeHUh?=
NCI-H720 M2X1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInXXlZKSzVyPUKuNlA3QTlizszN MkL0V2FPT0WU
EW-3 M2TtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K3[mlEPTB;Mj6yO|U{PCEQvF2= M33FUXNCVkeHUh?=
D-566MG NIfL[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLxTWM2OD1{LkS0OVY5KM7:TR?= NILk[FFUSU6JRWK=
697 MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHSTWM2OD1{Lki0NVc{KM7:TR?= MmL6V2FPT0WU
ES5 NHHXd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrvbGVKSzVyPUKuPFgyQDlizszN MXzTRW5ITVJ?
COLO-684 Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[xTWM2OD1|LkWxOlk3KM7:TR?= MoLLV2FPT0WU
ML-2 NHTjfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jvdGlEPTB;Mz62NFA2QCEQvF2= MVfTRW5ITVJ?
MC-IXC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XrOmlEPTB;Mz62N|M6OyEQvF2= MmfCV2FPT0WU
DB NHPNSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nte2lEPTB;Mz62OVQ1QCEQvF2= NVLQSYZ{W0GQR1XS
HCC2218 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNwN{OxNFMh|ryP NF3Bem9USU6JRWK=
NCI-H510A NH7WVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3idGlJUUN3ME2zMlgzPzJ2IN88US=> MmnyV2FPT0WU
NCI-H526 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDHc4hKSzVyPUOuPFY6PThizszN NFWxRVhUSU6JRWK=
MV-4-11 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTkWnRVUUN3ME20MlE{OzN2IN88US=> NFn5SJBUSU6JRWK=
PA-1 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRwMkWyPUDPxE1? M1j3cHNCVkeHUh?=
EW-22 M{TKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHvTWM2OD12LkO1PFYh|ryP MlPPV2FPT0WU
KASUMI-1 NFX0eHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLwTWM2OD12LkSwNVA6KM7:TR?= NG\G[4FUSU6JRWK=
LU-139 M1nBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC5[HdZUUN3ME20Mlc2QDJ7IN88US=> M{HIdXNCVkeHUh?=
SBC-1 M4TNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ETWM2OD12LkiwPVA5KM7:TR?= M4DWRnNCVkeHUh?=
H4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLMN5czUUN3ME20Mlg6PDR|IN88US=> NUj6S4Z2W0GQR1XS
EW-11 M1fzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jBZmlEPTB;NT6wPFA4OiEQvF2= MVHTRW5ITVJ?
NBsusSR M1XHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q2TWlEPTB;NT6xNlA2PSEQvF2= NXLtRYlZW0GQR1XS
RPMI-8226 NWm2UndVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe3NFY2UUN3ME21MlE2OjR2IN88US=> NV3RV3VXW0GQR1XS
DEL NELJfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DyS2lEPTB;NT6yNFAxPiEQvF2= M4rHN3NCVkeHUh?=
ES4 M2jsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y0fGlEPTB;NT61NVM5QSEQvF2= MkLjV2FPT0WU
GCT MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLINZVKSzVyPUWuOVY5PTZizszN NF3peWtUSU6JRWK=
NCI-H1048 NYftN5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTVwOUeyO|Mh|ryP NVT1fnpZW0GQR1XS
NCI-SNU-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOyWoNKSzVyPU[uNFIzKM7:TR?= MV\TRW5ITVJ?
ES7 M4L6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qyOGlEPTB;Nj6wN|U4PyEQvF2= M3nOb3NCVkeHUh?=
SW982 NEPLSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37n[2lEPTB;Nj6wPVE{PyEQvF2= NEHQUFdUSU6JRWK=
L-363 NH3Xc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnTTWM2OD14LkOzPVc1KM7:TR?= Mlj3V2FPT0WU
HT-1080 NWD3XlNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jjNWlEPTB;Nj60PVY5OyEQvF2= M4PQPXNCVkeHUh?=
HAL-01 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTZwNUGwPUDPxE1? NXTNc5BwW0GQR1XS
NB14 M{LPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTZwNkSwN|kh|ryP M{S1eHNCVkeHUh?=
EW-13 NWDTWXZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXHR3FKSzVyPU[uO|c1OjRizszN NXL3WXduW0GQR1XS
NY M{HSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF32dHdKSzVyPU[uPVQ3ODVizszN Mn7OV2FPT0WU
NCI-SNU-5 NHTTR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTdwMUC0N|Mh|ryP NYHFfWJIW0GQR1XS
MS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf1TWM2OD15LkG3OFk1KM7:TR?= Mn3KV2FPT0WU
EW-16 NILWeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTdwM{G4OlEh|ryP MUjTRW5ITVJ?
LU-65 NXX1NpNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzmcG5KSzVyPUeuOFg1OTdizszN NVfzW2pUW0GQR1XS
HGC-27 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTdwN{KxO|Mh|ryP NH3KdVdUSU6JRWK=
CTB-1 NWHOeFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TyRmlEPTB;Nz63OlE4PSEQvF2= M3HpbXNCVkeHUh?=
5637 NF\6e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTRTWM2OD15LkmyPFYh|ryP MmXvV2FPT0WU
U251 NYDwNYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID5bmpKSzVyPUeuPVQxOTZizszN MnviV2FPT0WU
HOS Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXCTWM2OD16LkKzNFA4KM7:TR?= NX7JcXZHW0GQR1XS
DOHH-2 M1ftd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRThwMkO1PEDPxE1? M1fpPHNCVkeHUh?=
EW-1 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRThwM{CwPFgh|ryP NFvP[JVUSU6JRWK=
BV-173 M{TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRThwNUW1OEDPxE1? MX3TRW5ITVJ?
8-MG-BA M3T5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRThwNki5PFgh|ryP M4PubXNCVkeHUh?=
NB69 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHCbotKSzVyPUiuO|A6OjFizszN Mkn1V2FPT0WU
NCI-H69 M33VS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDNZlFKSzVyPUmuPVA6PjFizszN NYm0R4x{W0GQR1XS
RS4-11 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;VNmtSUUN3ME2xNU4zOjB6IN88US=> NVu0ZnlrW0GQR1XS
ONS-76 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnOTWM2OD1zMT6yPVQ4KM7:TR?= M1TBWXNCVkeHUh?=
SF539 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LUVmlEPTB;MUGuOFg5QSEQvF2= MkTMV2FPT0WU
HuO-3N1 M2PLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr1NmpTUUN3ME2xNU42Pzl4IN88US=> MnHNV2FPT0WU
NCI-H1651 NETtdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjPc2w5UUN3ME2xNk4{OTF3IN88US=> MoLvV2FPT0WU
KARPAS-45 NXnadlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\Lc41HUUN3ME2xNk4{PzZizszN NYf4NZRxW0GQR1XS
SK-NEP-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTUTWM2OD1zMj60OlA6KM7:TR?= MVLTRW5ITVJ?
LAMA-84 NF;zemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInDeWVKSzVyPUGzMlExQTVizszN M2\QPXNCVkeHUh?=
NCI-H1155 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf6WHlKSzVyPUGzMlI5PTZizszN NX7nR5NTW0GQR1XS
CTV-1 NYraUXliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfTTWM2OD1zMz60OFUh|ryP MlLtV2FPT0WU
QIMR-WIL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13RN2lEPTB;MUOuO|gyPCEQvF2= M1\DZXNCVkeHUh?=
H9 NHLMW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnBUpVHUUN3ME2xN{45PDd3IN88US=> MnzHV2FPT0WU
SK-MEL-1 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD2bHNKSzVyPUGzMlk{PDdizszN NF\sUG9USU6JRWK=
HD-MY-Z NYTrW5FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfNeI9KSzVyPUG0MlA3OzdizszN M{TMVHNCVkeHUh?=
TI-73 NFrsZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ixN2lEPTB;MUSuNlM2PiEQvF2= NYTCcGRrW0GQR1XS
JVM-3 NFfWbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDMUnpKSzVyPUG1MlU4OTZizszN MX\TRW5ITVJ?
D-247MG NFXN[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHMOo5KSzVyPUG1MlU6OyEQvF2= NHziNlhUSU6JRWK=
VA-ES-BJ NIHrdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Wy[WlEPTB;MUWuOlA6PyEQvF2= M1TFSHNCVkeHUh?=
NOS-1 M3TSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K5e2lEPTB;MUWuOlUzOiEQvF2= NGPNZmZUSU6JRWK=
MOLT-4 NV\5fm1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrDUpd1UUN3ME2xOk44PTJizszN NFz0V|hUSU6JRWK=
Mo-T NHLObmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF5LkC4OFkh|ryP M{f2U3NCVkeHUh?=
NCI-H1770 M3naO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDJfmRKSzVyPUG3MlE2PDNizszN MlvoV2FPT0WU
COLO-320-HSR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPVRW1LUUN3ME2xO{4yQDJ5IN88US=> NXjw[3I4W0GQR1XS
TE-12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrMVYJyUUN3ME2xO{44ODV2IN88US=> M2q5ZnNCVkeHUh?=
NCI-H82 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O2XWlEPTB;MUeuPFczQCEQvF2= NXfQdIF4W0GQR1XS
NEC8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnETWM2OD1zOD6xN|E3KM7:TR?= MkS0V2FPT0WU
HSC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLQTllKSzVyPUG4Mlc1OTRizszN NWWwSlBUW0GQR1XS
NCI-H1092 NVnLZWFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvVTmJKSzVyPUG4Mlc2QTVizszN M1Lhb3NCVkeHUh?=
NCI-H292 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq0TWM2OD1zOT6wOFg6KM7:TR?= NFfrTVRUSU6JRWK=
L-428 NVLVb2J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF7LkW1PUDPxE1? M1PZXXNCVkeHUh?=
LU-134-A M2LpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWzTWM2OD1zOT61O|Ih|ryP NYO4XVdlW0GQR1XS
GI-ME-N M{Ttc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF7LkW3OFch|ryP NE\JfHJUSU6JRWK=
ALL-PO NEfnT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLHclRKSzVyPUG5MlU6PzJizszN NITid5JUSU6JRWK=
D-283MED MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fz[2lEPTB;MUmuPVE2KM7:TR?= NGnuT4xUSU6JRWK=
D-423MG NEDvSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF7Lkm5Olch|ryP NUTaNI9nW0GQR1XS
CAKI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i5T2lEPTB;MkCuNlIyQSEQvF2= Mmi2V2FPT0WU
ETK-1 M2TDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWwXlVlUUN3ME2yNE4zPjF3IN88US=> MlqwV2FPT0WU
G-402 NYT4[4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfsR4xKSzVyPUKwMlU{OzRizszN MXTTRW5ITVJ?
HL-60 Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD1{MT6xOlE{KM7:TR?= NEDhUZNUSU6JRWK=
A2058 NFnO[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;YTmlEPTB;MkGuOFQ4PyEQvF2= M{XrXnNCVkeHUh?=
CHP-212 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M333c2lEPTB;MkGuPVA2OSEQvF2= NXyyZpRFW0GQR1XS
KY821 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HHU2lEPTB;MkGuPVc2KM7:TR?= MnnMV2FPT0WU
TYK-nu MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XjW2lEPTB;MkKuNFY2OSEQvF2= MmrSV2FPT0WU
JVM-2 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r1cGlEPTB;MkKuNlk5OyEQvF2= MVjTRW5ITVJ?
KU812 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfpTWM2OD1{Mj63N|EzKM7:TR?= NEjYR2FUSU6JRWK=
MKN28 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XVSGlEPTB;MkKuPVAyPSEQvF2= NFLwSm5USU6JRWK=
ECC10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnnTWM2OD1{Mz63OFEh|ryP NUC5[WxTW0GQR1XS
BHT-101 M4\YNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ2LkCwNFgh|ryP NH3pXXVUSU6JRWK=
DU-4475 NFXOfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJ2LkOzN|ch|ryP NVjoXWt[W0GQR1XS
769-P NWOzWGxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjVRYZKSzVyPUK0Mlg1PjZizszN NFX5[29USU6JRWK=
HEC-1 M3fVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ3LkS0OUDPxE1? MkT2V2FPT0WU
MOLT-13 M1TDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4PYFOUUN3ME2yOU42OzNzIN88US=> MoS3V2FPT0WU
8505C NH3CS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT2bnpKSzVyPUK2MlQ6PzdizszN M2[zSHNCVkeHUh?=
GB-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ4LkexO|Yh|ryP MYPTRW5ITVJ?
SF126 M{H1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTsR2VwUUN3ME2yOk44PjR6IN88US=> MnH4V2FPT0WU
A4-Fuk NFHFNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j5emlEPTB;MkeuNVI4OSEQvF2= MYXTRW5ITVJ?
OVCAR-8 NVvUOHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTPZXpKSzVyPUK3MlE2OzlizszN M37y[XNCVkeHUh?=
NCI-H1304 M1SwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TLSmlEPTB;MkeuOVQh|ryP NXXFdYVpW0GQR1XS
GR-ST MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDofmRKSzVyPUK4MlA1PyEQvF2= MVzTRW5ITVJ?
G-401 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ6LkWwPVYh|ryP NEfmZ4pUSU6JRWK=
LXF-289 M4jZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHYSI1oUUN3ME2yPE42PjVzIN88US=> MWHTRW5ITVJ?
DBTRG-05MG NFO4T5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK5N4hKSzVyPUK4MlkzODRizszN NXjUdlR1W0GQR1XS
YKG-1 NHnq[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTxRohuUUN3ME2yPU45PjhizszN Mof5V2FPT0WU
GAMG NHjyTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHuTWQ4UUN3ME2yPU46QTNizszN MUnTRW5ITVJ?
HCT-116 M4jPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{KxWGlEPTB;M{CuNFU1QCEQvF2= NGnNc|VUSU6JRWK=
S-117 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPnbFY{UUN3ME2zNU4zOjV5IN88US=> NU\rVGUyW0GQR1XS
NCI-H1693 M3vubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13ONWlEPTB;M{OuOlU1OiEQvF2= MnvhV2FPT0WU
A427 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonTTWM2OD1|Mz65PVc3KM7:TR?= NIXvZ2FUSU6JRWK=
HT-29 NXn3TWRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN2Lk[wN|Ih|ryP MVfTRW5ITVJ?
P12-ICHIKAWA M1LJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO0OoptUUN3ME2zOE44PDlzIN88US=> NV\JTlRLW0GQR1XS
CAL-51 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrJTWM2OD1|NT6wO|A6KM7:TR?= MXjTRW5ITVJ?
Ramos-2G6-4C10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PZWGlEPTB;M{WuNlQzPSEQvF2= MoTkV2FPT0WU
SCH NVnOXXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPlboNKSzVyPUO2MlQyPzRizszN M4m3VnNCVkeHUh?=
SK-MEL-24 M1rob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTN4LkmwOFQh|ryP NXq5OY9nW0GQR1XS
SW1573 NIDXco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN6LkeyNVYh|ryP M2TUTHNCVkeHUh?=
BALL-1 M4fDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3yzWmlEPTB;M{muNlEzQSEQvF2= NVjtSoJ4W0GQR1XS
BE-13 NUfJUphHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\UZmlEPTB;M{muN|I6KM7:TR?= NWHQb2ZiW0GQR1XS
GI-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;jTWM2OD1|OT64OlQ4KM7:TR?= MnfvV2FPT0WU
GOTO NIfKTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SzZ2lEPTB;M{muPVE{QSEQvF2= NYi3XFNnW0GQR1XS
A673 NHS2cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRzLkCzOFMh|ryP MW\TRW5ITVJ?
KG-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTR|LkO5OEDPxE1? NHPJbpdUSU6JRWK=
GP5d MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTR2LkC2OlYh|ryP MmjPV2FPT0WU
MFM-223 M4\1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHwSXJUUUN3ME20OE4yOjJ6IN88US=> NX;WRXFSW0GQR1XS
OAW-42 NF25bGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfaS5dqUUN3ME20OE4zPjR|IN88US=> NH63d|FUSU6JRWK=
C8166 NUXKXW5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR3LkC4NlIh|ryP MkT5V2FPT0WU
LU-99A M322fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XXZlpUUN3ME20Ok4yOzJ{IN88US=> NUP3TYIzW0GQR1XS
NCI-H23 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrvV|U3UUN3ME20Ok4yPzh3IN88US=> NWjmUmM1W0GQR1XS
HO-1-N-1 M4Labmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon4TWM2OD12Nz6wPVk5KM7:TR?= M{TLTXNCVkeHUh?=
A3-KAW NHjwTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL3UJBKSzVyPUS3MlExODdizszN NFHHUZRUSU6JRWK=
CGTH-W-1 NYTmcI05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorJTWM2OD12Nz61NFY6KM7:TR?= MU\TRW5ITVJ?
DJM-1 NVLYUoJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETReoNKSzVyPUS3MlU1OTNizszN M{TDO3NCVkeHUh?=
A101D Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInVemVKSzVyPUS3MlY{PTdizszN MoHvV2FPT0WU
BB30-HNC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnubnBKSzVyPUS4MlMxPzJizszN M1XscXNCVkeHUh?=
T98G NUfK[VR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTR6LkS2N|Mh|ryP NXP1V3JYW0GQR1XS
NCI-H1573 M3;hTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR7LkS0OlIh|ryP NHftSlVUSU6JRWK=
MEG-01 NVzlR|hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWriSZZVUUN3ME20PU44PDFzIN88US=> MkfZV2FPT0WU
WM-115 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\nZWlEPTB;NEmuPVIzOiEQvF2= MonRV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 Olaparib有效作用于Brca1-/-;p53-/- 乳腺肿瘤 (每天按50 mg/kg剂量腹腔注射),但是对 HR缺陷的Ecad-/-;p53-/-乳腺肿瘤没有效果。Olaparib作用于携带肿瘤的鼠没有剂量限制毒性。[3] Olaparib已经用于治疗BRCA突变的肿瘤, 比如卵巢癌,胸腺癌,前列腺癌。此外,Olaparib抑制ATM缺陷的肿瘤细胞具有选择性,说明Olaparib可作为治疗ATM突变的淋巴肿瘤的潜在试剂。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

体外独立酶实验:

通过PARP-1实验测定PARP-2抑制活性,实验在96孔板上进行,PARP-2特定抗体与重组PARP-2蛋白结合。加入3H-NAD+DNA测定PARP-2活性。 冲洗后,加入闪烁剂测定3H-渗透的核糖基化。通过AlphaScreen实验测定端锚聚合酶-1, 实验中HIS标签重组TANK-1蛋白和生物素化的NAD+ 在384孔Proxi板上温育。 加入Alpha 磁珠,与HIS和生物素化的标签结合,产生邻近信号,测定信号消失的比例来计算TANK-1抑制活性。
细胞实验:

[1]

+ 展开
  • Cell lines: 胸腺癌细胞系SW620结肠, A2780卵巢,HCC1937,Hs578T,MDA-MB-231,MDA-MB-436,和T47D
  • Concentrations: 1到300 nM
  • Incubation Time: 7-14天
  • Method:

    通过成株实验测定Olaparib毒性。Olaparib溶于DMSO中,用培养基稀释。细胞接种在六孔板上,过夜使粘附。然后加入不同浓度Olaparib,温育7-14天。计算存活菌落,测定IC50值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 携带Brca1-/-;p53-/-乳腺癌的 K14cre;Brca1F/F;p53F/F
  • Formulation: 50 mg/mL储存在含10% 2-羟丙基-β-环糊精/PBS的DMSO中
  • Dosages: 50 mg/kg
  • Administration: 按10 μL/g剂量腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 434.46
化学式

C24H23FN4O3

CAS号 763113-22-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03462342 Recruiting High Grade Serous Carcinoma University of Pennsylvania|AstraZeneca March 9 2018 Phase 2
NCT03117933 Recruiting Ovarian Cancer University of Oxford|AstraZeneca March 9 2017 Phase 2
NCT03106987 Recruiting Epithelial Ovarian Cancer AstraZeneca|European Network of Gynaecological Oncological Trial Groups (ENGOT) June 8 2017 Phase 3
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 8 2015 Phase 1|Phase 2
NCT00679783 Active not recruiting Ovarian Carcinoma|Breast Cancer AstraZeneca|British Columbia Cancer Agency July 8 2008 Phase 2
NCT03579316 Not yet recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Ovarian Carcinoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) September 7 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • 回答:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • 问题 2:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • 回答:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)供应商 | 采购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)价格 | Olaparib (AZD2281, Ku-0059436)生产 | 订购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID